The Role of L-arginine in the Endothelial Dysfunction
NCT00583388 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2015-04-28
Summary
Acute cardiac and vascular events, like heart attack and sudden cardiac death manifest a clear surge in the early morning hours around the time of waking, so that their peak onset is between 6AM and 11AM. The mechanisms are not fully understood, but we had shown that healthy subjects have impaired vascular reactivity in the early morning (endothelial dysfunction). This is associated with a decrease in nitric oxide levels (a substance that promotes vasodilatation). We also have described that vessel reactivity and the levels of this substance can recover by noon only when people breakfast.
L-arginine is a semi-essential amino acid found in large quantities in chicken, in fish, and beans and is the substrate for the production of nitric oxide Therefore we want to test if there is a beneficial effect of administration of L-arginine on the circadian pattern of vessel reactivity. Our goal is to understand why cardiovascular events are more likely to happen in the early morning and how to prevent.
The research will help us to understand the efficacy, acute effects and tolerability of high doses of L-arginine. This can lead to future research to assess long term effects of L-arginine supplements to prevent cardiovascular events in the early morning hours.
Conditions
- Healthy
Interventions
- DIETARY_SUPPLEMENT
-
L-arginine
Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
- DEVICE
-
Ultrasound
Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Virend K Somers, MD, PhD · Mayo Clinic
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2010-06-30
- Completion
- 2010-06-30
More Related Trials
-
Nitric Oxide Supplementation in Argininosuccinic Aciduria
NCT02252770 ·Status: COMPLETED ·Phase: NA
-
L-citrulline Supplementation During Sepsis
NCT00628381 ·Status: UNKNOWN ·Phase: PHASE3
-
Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP
NCT00584350 ·Status: UNKNOWN ·Phase: PHASE4
-
REduction of rIsk for Contrast Induced Nephropathy
NCT01402232 ·Status: UNKNOWN
-
Effect of Carnitine on Uremic Cardiomyopathy
NCT02322697 ·Status: COMPLETED ·Phase: NA
-
N-Acetylcysteine and Arginine Administration in Diabetic Patients
NCT00569465 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
NCT01722513 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients
NCT00161369 ·Status: COMPLETED
-
Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration
NCT01786824 ·Status: TERMINATED ·Phase: PHASE3
-
Plasma S-adenosylhomocysteine Levels and Endothelial Dysfunction
NCT03345927 ·Status: COMPLETED
-
Effect of Sublingually Generated S-nitroso-N-acetylcysteine on Systemic Blood Pressure.
NCT05798481 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
NCT05271448 ·Status: UNKNOWN ·Phase: NA
-
Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography
NCT01144091 ·Status: WITHDRAWN ·Phase: NA
-
Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein
NCT00463749 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms
NCT02125890 ·Status: COMPLETED ·Phase: PHASE3
-
Relevance of Flavanols for Cardiovascular Function in End-Stage Renal Disease
NCT00835887 ·Status: WITHDRAWN ·Phase: PHASE2
-
Prevention of Serious Adverse Events Following Angiography
NCT01467466 ·Status: COMPLETED ·Phase: PHASE3
-
Renoprotective Effects of Fluid Prophylaxis Strategies for Contrast Induced Nephropathy (CIN)
NCT00749827 ·Status: WITHDRAWN ·Phase: PHASE4
-
The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy
NCT00494637 ·Status: TERMINATED ·Phase: NA
-
NITRATE-OCT-CIN (Sub-Study of NITRATE-OCT)
NCT05544981 ·Status: COMPLETED ·Phase: NA
-
Coenzyme Q10 Role in Prevention of Contrast Induced Nephropathy in Acute Coronary Syndrome Patients.
NCT06429345 ·Status: RECRUITING ·Phase: PHASE4
-
Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR
NCT05350683 ·Status: COMPLETED ·Phase: PHASE2
-
The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
NCT02575092 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Preventing Contrast Nephropathy With Sodium Bicarbonate in Patients With Pulmonary Edema,Heart Failure,Uncontrolled HTN
NCT00513825 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction
NCT01160627 ·Status: COMPLETED ·Phase: NA